Sign up to save your podcasts
Or
Share A New Era for Urticaria Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Era for Urticaria Treatment
In this short, conference-based episode, Professor Torsten Zuberbier, President of Global Allergy and Asthma Excellence Network, speaks with Professor Kiran Godse from Mumbai, India, directly from the UCARE Urticaria Conference, sharing the latest breakthroughs in urticaria research and treatment.
The discuss:
🔹 What are the most important new developments in urticaria therapy?
🔹 How do BTK inhibitors change the way chronic urticaria is treated?
🔹 Why can these new drugs work in both autoimmune and autoallergic urticaria?
🔹 How can digital tools like the CRUSE App support patients and physicians?
Professor Godse highlights the rapid progress made over the past year, including the emergence of novel oral therapies that caneffectively control most forms of chronic urticaria. The discussion focuses on BTK inhibitors, which act inside the mast cell to block histamine release at its source, offering a new, convenient tablet-based treatment option. In addition, the episode emphasizes the growing role of digital patient tools, such as the CRUSE App, which help patients monitor disease activity and support personalized treatment decisions worldwide.
Key Learnings from the Episode:
Chronic urticaria consists of autoallergic and autoimmune subtypes, both of which can be targeted by new BTK inhibitors.
BTK inhibitors block mast-cell signaling inside the cell, preventing histamine release and reducing symptoms effectively.
New oral therapies offer once- or twice-daily tablet options, improving convenience and adherence for patients.
Several new urticaria treatments have been approved globally, with wider availability expected soon.
The CRUSE App enables patients to track disease activity and supports data-driven clinical decisions.
Digital tools improve doctor–patient communication and help personalize treatment strategies.
Global initiatives like UCARE are transforming urticaria care through research, education, and collaboration.
The outlook for urticaria patients is increasingly positive, with more effective and accessible treatments emerging worldwide.
Chapters:
00:00 Introduction to UCARE Conference
01:31 New Developments in Urticaria Treatment
03:22 Innovative Apps for Patient Management
View all episodes
By UCARE, the Global Allergy and Asthma Excellence Network for UrticariaIn this short, conference-based episode, Professor Torsten Zuberbier, President of Global Allergy and Asthma Excellence Network, speaks with Professor Kiran Godse from Mumbai, India, directly from the UCARE Urticaria Conference, sharing the latest breakthroughs in urticaria research and treatment.
The discuss:
🔹 What are the most important new developments in urticaria therapy?
🔹 How do BTK inhibitors change the way chronic urticaria is treated?
🔹 Why can these new drugs work in both autoimmune and autoallergic urticaria?
🔹 How can digital tools like the CRUSE App support patients and physicians?
Professor Godse highlights the rapid progress made over the past year, including the emergence of novel oral therapies that caneffectively control most forms of chronic urticaria. The discussion focuses on BTK inhibitors, which act inside the mast cell to block histamine release at its source, offering a new, convenient tablet-based treatment option. In addition, the episode emphasizes the growing role of digital patient tools, such as the CRUSE App, which help patients monitor disease activity and support personalized treatment decisions worldwide.
Key Learnings from the Episode:
Chronic urticaria consists of autoallergic and autoimmune subtypes, both of which can be targeted by new BTK inhibitors.
BTK inhibitors block mast-cell signaling inside the cell, preventing histamine release and reducing symptoms effectively.
New oral therapies offer once- or twice-daily tablet options, improving convenience and adherence for patients.
Several new urticaria treatments have been approved globally, with wider availability expected soon.
The CRUSE App enables patients to track disease activity and supports data-driven clinical decisions.
Digital tools improve doctor–patient communication and help personalize treatment strategies.
Global initiatives like UCARE are transforming urticaria care through research, education, and collaboration.
The outlook for urticaria patients is increasingly positive, with more effective and accessible treatments emerging worldwide.
Chapters:
00:00 Introduction to UCARE Conference
01:31 New Developments in Urticaria Treatment
03:22 Innovative Apps for Patient Management